Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.

Aldinucci D, Borghese C, Casagrande N.

Int J Mol Sci. 2019 May 15;20(10). pii: E2416. doi: 10.3390/ijms20102416. Review.


Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives.

Altaf M, Casagrande N, Mariotto E, Baig N, Kawde AN, Corona G, Larcher R, Borghese C, Pavan C, Seliman AA, Aldinucci D, Isab AA.

Cancers (Basel). 2019 Apr 4;11(4). pii: E474. doi: 10.3390/cancers11040474.


CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D.

Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.


Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.

Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D.

Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216.


New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.

Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA.

Oncotarget. 2017 Jan 3;8(1):490-505. doi: 10.18632/oncotarget.13448.


Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D.

Blood. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365. Epub 2015 Jul 30. No abstract available.


Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Clin Cancer Res. 2014 Nov 1;20(21):5496-506. doi: 10.1158/1078-0432.CCR-14-0713. Epub 2014 Sep 17.


Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.

Celegato M, Fregona D, Mongiat M, Ronconi L, Borghese C, Canzonieri V, Casagrande N, Nardon C, Colombatti A, Aldinucci D.

Future Med Chem. 2014 Jul;6(11):1249-63. doi: 10.4155/fmc.14.81.


The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, Carbone A, Aldinucci D.

Cancer Lett. 2014 Jul 10;349(1):26-34. doi: 10.1016/j.canlet.2014.03.030. Epub 2014 Apr 2.


Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Gynecol Oncol. 2013 Dec;131(3):744-52. doi: 10.1016/j.ygyno.2013.08.041. Epub 2013 Sep 10.


Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.

Celegato M, Borghese C, Casagrande N, Carbone A, Colombatti A, Aldinucci D.

Leuk Lymphoma. 2014 Jan;55(1):149-59. doi: 10.3109/10428194.2013.800196. Epub 2013 Jun 12.


Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.

Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, Mazzucato M, Celegato M, Colombatti A, Aldinucci D.

J Cell Biochem. 2013 May;114(5):1135-44. doi: 10.1002/jcb.24456.


Pitfalling in nanomedical targeting of melanoma: a 'clinical' case of misdelivered RNAi.

Perris R, Borghese C, Magro G.

Pigment Cell Melanoma Res. 2011 Oct;24(5):980-2; author reply 983-5. doi: 10.1111/j.1755-148X.2011.00888.x. No abstract available.


IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.

Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A.

Br J Haematol. 2011 Jan;152(2):182-90. doi: 10.1111/j.1365-2141.2010.08497.x. Epub 2010 Nov 28.


Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.

Magro G, Schiappacassi M, Perissinotto D, Corsaro A, Borghese C, Belfiore A, Colombatti A, Grasso S, Botti C, Bombardieri E, Perris R.

J Pathol. 2003 Jul;200(3):357-69.


Supplemental Content

Loading ...
Support Center